Effects of the adrenergic receptor blocking agents on the ganglionic transmission.
D000200:Action Potentials / Q000187:drug effects*; D000317:Adrenergic alpha-Antagonists / Q000494:pharmacology; D000319:Adrenergic beta-Antagonists / Q000494:pharmacology; D000818:Animals; D004837:Epinephrine / Q000037:antagonists & inhibitors*; D004878:Ergotamine / Q000494:pharmacology; D004983:Ethanolamines / Q000494:pharmacology; D005071:Evoked Potentials / Q000187:drug effects; D005725:Ganglia, Autonomic / Q000187:drug effects*; D005730:Ganglionic Blockers / Q000037:antagonists & inhibitors; D007269:Injections, Intra-Arterial; D007275:Injections, Intravenous; D010646:Phentolamine / Q000494:pharmacology; D011433:Propranolol / Q000494:pharmacology; D011817:Rabbits; D013565:Sympatholytics / Q000494:pharmacology*; D009435:Synaptic Transmission / Q000187:drug effects*
D000317:Adrenergic alpha-Antagonists; D000319:Adrenergic beta-Antagonists; D004983:Ethanolamines; D005730:Ganglionic Blockers; D013565:Sympatholytics; D011433:Propranolol; D004878:Ergotamine; D004837:Epinephrine; D010646:Phentolamine